EP4739776A2 - Arn antisens longs non codants pour la modification de l'expression génique et pour des applications thérapeutiques - Google Patents

Arn antisens longs non codants pour la modification de l'expression génique et pour des applications thérapeutiques

Info

Publication number
EP4739776A2
EP4739776A2 EP24738218.7A EP24738218A EP4739776A2 EP 4739776 A2 EP4739776 A2 EP 4739776A2 EP 24738218 A EP24738218 A EP 24738218A EP 4739776 A2 EP4739776 A2 EP 4739776A2
Authority
EP
European Patent Office
Prior art keywords
region
nucleotides
incrna
antisense
length
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24738218.7A
Other languages
German (de)
English (en)
Inventor
Heike KREBBER
Holger BASTIANS
Cesur Ivo COBAN
Jan-Philipp LAMPING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georg August Universitaet Goettingen Stiftung Oeffentlichen Rechts Universitaetsmedizin
Georg August Universitaet Goettingen
Universitaetsmedizin Goettingen Georg August Universitaet
Original Assignee
Georg August Universitaet Goettingen Stiftung Oeffentlichen Rechts Universitaetsmedizin
Georg August Universitaet Goettingen
Universitaetsmedizin Goettingen Georg August Universitaet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georg August Universitaet Goettingen Stiftung Oeffentlichen Rechts Universitaetsmedizin, Georg August Universitaet Goettingen, Universitaetsmedizin Goettingen Georg August Universitaet filed Critical Georg August Universitaet Goettingen Stiftung Oeffentlichen Rechts Universitaetsmedizin
Publication of EP4739776A2 publication Critical patent/EP4739776A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne un ARN antisens long non codant (ARNaslnc) qui peut former un complexe double brin (ds) partiel avec un ARNm cellulaire correspondant dans des cellules eucaryotes et un complexe biologique comprenant l'ARNlnc antisens et un ARNm cible qui peuvent former ensemble un complexe double brin partiel in vitro. Le complexe d'ARNdb est préférentiellement exporté à partir du noyau et traduit dans le cytoplasme, l'expression génique est ainsi amplifiée. Outre l'amplification des ARNaslnc, les ARNaslnc inhibiteurs sont divulgués. Un vecteur d'expression comprenant une séquence d'acide nucléique de l'ARNaslnc est également divulgué. La présente invention peut être utilisée pour augmenter ou diminuer l'exportation d'un ARNm cible à partir du noyau et ainsi, pour augmenter ou diminuer l'expression génique sans interférer avec l'ADN génomique ou avec des niveaux d'ARNm. Des procédés pour augmenter ou diminuer l'exportation et/ou l'expression d'un ARNm cible, des transfections de cellules à l'aide de plasmides exprimant l'ARNlnc antisens ou à l'aide de conjugués comprenant l'ARNaslnc, et une composition pharmaceutique comprenant l'ARNlnc sont également divulgués. L'ARNaslnc, le complexe, le vecteur d'expression et le conjugué sont utiles pour améliorer la production de protéines recombinantes qui sont utilisées dans des applications biotechnologiques et à des fins médicales. L'ARNaslnc est également utile pour augmenter la présentation d'antigène lors de la vaccination par ARNm.
EP24738218.7A 2023-07-08 2024-06-14 Arn antisens longs non codants pour la modification de l'expression génique et pour des applications thérapeutiques Pending EP4739776A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363512615P 2023-07-08 2023-07-08
PCT/EP2024/066684 WO2025011876A2 (fr) 2023-07-08 2024-06-14 Arn antisens longs non codants pour la modification de l'expression génique et pour des applications thérapeutiques

Publications (1)

Publication Number Publication Date
EP4739776A2 true EP4739776A2 (fr) 2026-05-13

Family

ID=91810379

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24738218.7A Pending EP4739776A2 (fr) 2023-07-08 2024-06-14 Arn antisens longs non codants pour la modification de l'expression génique et pour des applications thérapeutiques

Country Status (2)

Country Link
EP (1) EP4739776A2 (fr)
WO (1) WO2025011876A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121838875A (zh) * 2026-03-13 2026-04-10 山东第一医科大学(山东省医学科学院) 一种lincRNA小肽编码潜能鉴定方法及系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE141646T1 (de) 1986-04-09 1996-09-15 Genzyme Corp Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US6750059B1 (en) 1998-07-16 2004-06-15 Whatman, Inc. Archiving of vectors
AU2002336760A1 (en) 2001-09-26 2003-06-10 Mayo Foundation For Medical Education And Research Mutable vaccines
WO2011028929A2 (fr) 2009-09-03 2011-03-10 The Regents Of The University Of California Promoteur sensible aux nitrates

Also Published As

Publication number Publication date
WO2025011876A3 (fr) 2025-02-20
WO2025011876A2 (fr) 2025-01-16

Similar Documents

Publication Publication Date Title
Bossaert et al. Transcription-associated topoisomerase 2α (TOP2A) activity is a major effector of cytotoxicity induced by G-quadruplex ligands
JP7691113B2 (ja) バーコード化された細胞外小胞のライブラリー
EP3723732A1 (fr) Plateforme de distribution d'acide nucléique de vésicule extracellulaire de protéine arc
KR20160097327A (ko) 유전자 산물, 구조 정보 및 유도성 모듈형 ｃａｓ 효소의 발현의 변경을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 방법
KR20160097331A (ko) 뉴클레오티드 반복 장애에서의 ｃｒｉｓｐｒ-ｃａｓ 시스템의 조성물 및 방법 및 용도
US20120142764A1 (en) Multi-Cistronic shRNA Expression Cassette for Suppressing Single or Multiple Target Genes
JP4517061B2 (ja) ダンベル型ｄｎａの効率的な製造方法
Martins et al. Nuclear processing of nascent transcripts determines synthesis of full-length proteins and antigenic peptides
JP2023522020A (ja) 顔面肩甲上腕型筋ジストロフィーのためのｃｒｉｓｐｒ阻害
US11814626B2 (en) Compositions and methods for loading extracellular vesicles with chemical and biological agents/molecules
WO2022167009A1 (fr) Arnsg ciblant l'arnm de l'aqp1, et vecteur et utilisation associés
Feng et al. The role of miR‐326 in adipogenic differentiation of human adipose‐derived stem cells by targeting C/EBPα in vitro
WO2025011876A2 (fr) Arn antisens longs non codants pour la modification de l'expression génique et pour des applications thérapeutiques
Chen et al. CRISPR-based RNA-binding protein mapping in live cells
US20200157537A1 (en) Modulating RNA Interactions with Polycomb Repressive Complex 1 (PRC1)
JP5645171B2 (ja) 細胞増殖抑制剤及びそのスクリーニング方法
Sarkami et al. Engineering HEK293T cell line by lentivirus to produce miR34a-loaded exosomes
CN103505745A (zh) 小分子rna作为免疫抑制剂的应用
Xu et al. siRNA in vivo-targeted delivery to murine dendritic cells by oral administration of recombinant yeast
CN117202894A (zh) 负载至少两个不同核酸的细胞外囊泡
JP2022515211A (ja) 合成マイクロｒｎａミミック
WO2025160114A1 (fr) Compositions et méthodes pour le traitement de l'artériosclérose
US20260139278A1 (en) Specificity of crispr-transposon systems in dna modification
Jiang Functional characterization of histone variant H2A. B in Hodgkin lymphoma
JP4368936B2 (ja) 転写ｄｎａ結合部位を含む環状ダンベルデコイオリゴデオキシヌクレオチド（ｃｄｏｄｎ）

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260206

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR